N/A N=79 Leveraging Technology to Address Unhealthy Drug Use in Primary Care Settings
Addiction
Primary: Receipt of Brief Intervention (BI) for Drug Use at Baseline Visit — 17; 33 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=78 Stress, Distress Intolerance, and Drug Dependence
Substance Dependence
Primary: Percentage of Positive Toxicology Swabs for Illicit Substances — 81.3; 79.1; 86.2; 82.3 percentage of positive toxicology screen
N/A N=127 Cocaine Use Reduction and Health
Cocaine Use Disorder
Primary: Endothelin-1 Levels — 2.15; 2.063; 1.956 pg/ml
N/A N=55 Clinical Decision Support for Opioid Use Disorders in Medical Settings: Usability Testing in an EMR
Opioid-use Disorder
Primary: Intervention PCP Confidence in Assessing and Treating OUD — 6; 11; 8; 1 Participants
N/A N=29 Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.
Opioid-use Disorder
Primary: Treatment Retention — 5; 5 Participants — p==0.87
N/A N=368 Feasibility and Validation of a Standard Phenotyping Assessment Battery
Opioid-use Disorder · Cocaine Use Disorder · Marijuana Use Disorder
Primary: Retention — 4; 27; 10; 21 Participants
Phase 2 N=174 UH3 Varenicline for Cannabis Use Disorder
Cannabis Use Disorder
Primary: Efficacy of Varenicline vs. Placebo for Reducing Total Number of Weekly Cannabis Use Sessions — 10.3; 11.6; 9.4; 11.7 number of weekly use sessions
Phase 3 N=40 Glutamatergic Modulation of Disordered Alcohol Use
Alcohol Dependence
Primary: Percentage of Participants Demonstrating Alcohol Abstinence in the Control (Midazolam) Group Versus the Active (Ketamine) Group — 68.6; 98.6 percentage of participants
Phase 3 N=141 Treating Violence-Prone Substance Use Disorder Patients
Substance-related Disorders · Violence
Primary: Addiction Severity Index Legal Composite — .038; .012 units on a scale
Phase 2 N=72 Varenicline Treatment for Cannabis Use Disorder
Substance Use Disorder
Primary: Cannabis Withdrawal Symptoms During Active Treatment — 2.23; 3.94; 2.59; 4.07 score on a scale
Phase 2 N=13 Suvorexant for Opioid/Stimulant Co-use
Opioid Use Disorder · Stimulant Use Disorder
Primary: Opioid Use: Proportion of Positive Urine Drug Screens (UDS) — 0.83; 0.67 Proportion of urine drug screens
Phase 4 N=105 Bupropion for ADHD in Adolescents With Substance Use Disorder
Attention Deficit Hyperactivity Disorder · Nicotine Dependence · Cannabis Use Disorder
Primary: Change in ADHD Rating Scale (ADHD-RS) Total Score — -14.2; -13.8 units on a scale
Phase 1 N=20 Oxytocin, Stress, Craving, Opioid Use Disorder
Opioid Use Disorder
Primary: Opioid Craving — 21.6; 22.4; 23.3; 23.4 score on a scale
Early Phase 1 N=30 Behavioral Effects of Pregabalin and Cannabis
Cannabis-use Disorders
Primary: Number of Self-administered Puffs of Smoked Cannabis Containing Active THC Concentrations Compared to Placebo Under Controlled Laboratory Conditions — 2.00; 2.67; 3.60…
N/A N=5,706 Computerized Substance Use and Depression Screening and Behavioral Treatment in HIV Primary Care
Substance Use Disorders · HIV · Depression
Primary: Change in Mental Health and Substance Use Screening Rates — 2008; 2379 Participants
N/A N=150 Intensive Models of HCV Care for Injection Drug Users
Hepatitis C · Medication Adherence
Primary: Electronically Monitored Medication Adherence — 86; 80; 75 Percentage of medication taken
Phase 1 N=10 Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder
Cannabis Use Disorder
Primary: Self-report Instruments to Measure Cannabis Use — 26.72; 5.256 Inhalations of Cannabis Per Day
Phase 1 N=8 Facilitating the Behavioral Treatment of Cannabis Use Disorder
Cannabis Dependence
Primary: Percentage of Participants With Cannabis Abstinence or Significant Reduction in Cannabis Use — 7 Participants
N/A N=1,731 Opioid Use Disorder in the Emergency Department: CTN 0069
Opioid Use Disorder
Primary: Implementation (Considered the Primary Outcome) — 2; 53 Participants — p=<0.001
Early Phase 1 N=18 Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer
Active Cocaine Users
Primary: The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 0.06; 0.94; 0.75; 0.88 cocaine choices
N/A N=119 Stress Response in Opioid Use Disorder
Opioid-use Disorder
Primary: Change in Negative Affect — 1.67; 1.25; 3.60 scores on a scale
Phase 2 N=272 Lorcaserin in the Treatment of Cocaine Use Disorder
Cocaine-Related Disorders
Primary: The Primary Endpoint is the Actual Number of Subjects That Successfully Achieve Abstinence From Cocaine During the Last Three Weeks of Treatment in the "Pre-qualified…
N/A N=667 LINK: Aftercare Monitoring Project
Alcohol Dependence · Drug Dependence
Primary: Rates of Substance Use — 91.1; 88.0 percentage of days
Phase 2 N=63 Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress
Alcohol Use Disorder · Stress Disorders, Post-Traumatic · Anxiety Disorders
Primary: Change in Craving to Use Alcohol Rating (Visual Analog Scale) — 0.076; -0.928 score on a scale
N/A N=439 Implementing Technology-Assisted Drug Treatment and Relapse Prevention in Federally Qualified Health Centers (FQHCs)
Substance Use Disorders · HIV
Primary: Implementation Status — 12; 12; 12 milestones
N/A N=97 Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions
Drug Use · Alcohol Use · Congestive Heart Failure
Primary: Change in Substance Use Rates From Baseline — 51.37; 51.38; 35.53; 26.65 Days of Substance Use
Phase 3 N=303 Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)
ADHD · Substance Abuse
Primary: ADHD Severity — -20.6; -21.8 units on a scale
N/A N=200 Women's Treatment and Early Recovery
Substance-related Disorders
Primary: Treatment Completion — 43; 31 Number of women — p=<0.05
Early Phase 1 N=25 Imaging the Neurochemistry of Drug Addiction With PET
Smoking · Cannabis
Primary: Change in Dopamine Levels at Baseline and After Drug of Dependence Administration as Confirmed by PET Images. — 0.0388; 0.033; 0.0285; 0.0368 mm^3
N/A N=302 Exercise as a Treatment for Substance Use Disorders Protocol
Stimulant Abuse and Dependence
Primary: Percent Days Abstinent — 90.8; 91.6; 75.5; 77.2 Percentage of Days — p=<0.05